Business resources for Canadian pharmacists
As a trusted Canadian-owned pharmaceutical company, Apotex is proud to support pharmacists across Canada with tools and resources designed to strengthen your practice. We offer both business and practical resources, which are key building blocks to help you deliver exceptional pharmacy services and grow your business.
Our business and practice resources include:
The Apotex 360 Platform
Apotex 360 is an intuitive, modern digital platform serving as your all-in-one source for Apotex value-added programs, services, resources, and information. You can download the Apotex 360 app from the Apple Store or Google Play, or access the web version at www.apotex360.ca.
Pharmacists will find a wealth of valuable information, including:
- iPharmacist 360®: A quick, one-stop solution for medication, health, and clinical questions. Powered by Lexicomp™, an industry-leading provider of trusted drug and clinical information, this program helps you find reliable answers when you need them. Speak with your Apotex Sales Representative about accessing an annual subscription.
- Resources 360: Offers business tools like print-ready marketing materials to promote your pharmacy services, sales-boosting tips, and practice resources such as patient education pamphlets and instructional videos.
- News 360: Stay updated with daily news feeds covering national and provincial pharmacy industry developments across Canada.
- Apotex Products: A comprehensive listing of Apotex products and available strengths to support your pharmacy inventory and patient needs.
The Apotex Concierge Service
Pharmacy practice is evolving, and Apotex is here to help you adapt and thrive. Our dedicated Concierge Team connects you to a wide network of leading Canadian industry vendors and suppliers. Whether you need healthcare supplies, pharmacy renovation services, marketing expertise, or other support, we’ll help you find the right partners, so you can focus on delivering quality care to your patients.
Drug information support for Canadian healthcare professionals
DISpedia is Apotex's dedicated drug information service, created to support healthcare professionals with timely, accurate, and evidence-based information. Whether you're a pharmacist, physician, nurse, or other healthcare provider, our expert team is here to help — at no cost to you.
Our multidisciplinary team includes Canadian-licensed pharmacists, nurses, physicians, and medical students who are equipped to provide clear, unbiased responses to your drug- or product-related inquiries.
How we can help
Contact DISpedia for information related to:
- Apotex products and formulations
- General drug or disease-related questions
- Apotex programs and internal resources
- Special Access Program (SAP) inquiries
We’re committed to supporting clinical decisions with dependable, up-to-date information, so you can focus on delivering exceptional care.
Contact DISpedia
Hours of Operation:
Monday to Friday, 9:00 a.m. – 5:00 p.m. (EST)
Phone: 1-800-667-4708
ApoAssist
ApoSecure
Latest news
-
Sep 29, 2026
Apotex Health Corp. announces $1,250 million inaugural senior unsecured notes offering
Toronto, Ontario, September 28, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today that it has priced a private placement offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Notes are being offered on an agency basis by a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.
-
Sep 18, 2026
Apotex Health Corp. announces closing of upsized bought deal secondary offering
Toronto, Ontario, September 18, 2026 – Apotex Health Corp. ("Apotex" or the "Company") announced today the closing of the previously announced upsized secondary offering (the "Offering") of common shares of the Company (the "Common Shares") by an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders").
-
Sep 15, 2026
Apotex Health Corp. announces upsize of bought deal secondary offering to $850 million
Toronto, Ontario, September 15, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that, as a result of strong demand, Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an amended agreement with the syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to increase the size of the previously announced bought deal secondary offering of common shares of the Company (the "Common Shares"). Under the amended agreement, the Underwriters have agreed to purchase 25,000,000 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $850,000,000 (the "Upsized Offering").